Xiong Xingmin, Huang BenBen, Gan Zhe, Liu Weixiang, Xie Yang, Zhong Jianing, Zeng Xiangtai
Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, 323 National Road, Ganzhou, 341000, Jiangxi, China.
Heliyon. 2024 Jul 2;10(13):e34032. doi: 10.1016/j.heliyon.2024.e34032. eCollection 2024 Jul 15.
Thyroid cancer is the most common malignant tumor of the endocrine system, and evidence suggests that post-translational modifications (PTMs) and epigenetic alterations play an important role in its development. Recently, there has been increasing evidence linking dysregulation of ubiquitinating enzymes and deubiquitinases with thyroid cancer. This review aims to summarize our current understanding of the role of ubiquitination-modifying enzymes in thyroid cancer, including their regulation of oncogenic pathways and oncogenic proteins. The role of ubiquitination-modifying enzymes in thyroid cancer development and progression requires further study, which will provide new insights into thyroid cancer prevention, treatment and the development of novel agents.
甲状腺癌是内分泌系统最常见的恶性肿瘤，证据表明翻译后修饰（PTMs）和表观遗传改变在其发展过程中起重要作用。最近，越来越多的证据表明泛素化酶和去泛素化酶的失调与甲状腺癌有关。本综述旨在总结我们目前对泛素化修饰酶在甲状腺癌中的作用的理解，包括它们对致癌途径和致癌蛋白的调控。泛素化修饰酶在甲状腺癌发生和发展中的作用需要进一步研究，这将为甲状腺癌的预防、治疗和新型药物的开发提供新的见解。
